Immunome, Inc. (NASDAQ:IMNM – Get Free Report) has earned a consensus rating of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have covered the stock in the last year is $29.80.
Several research analysts have recently issued reports on the company. Piper Sandler began coverage on Immunome in a research note on Friday, May 31st. They set an “overweight” rating and a $27.00 price target for the company. Wedbush reissued an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Thursday, July 25th. JPMorgan Chase & Co. began coverage on shares of Immunome in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 target price for the company. Finally, Guggenheim initiated coverage on shares of Immunome in a research note on Monday, April 15th. They issued a “buy” rating and a $35.00 target price for the company.
Read Our Latest Stock Report on IMNM
Insider Transactions at Immunome
Hedge Funds Weigh In On Immunome
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Immunome in the second quarter valued at approximately $97,000. EntryPoint Capital LLC grew its position in Immunome by 21,864.0% in the first quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after acquiring an additional 5,466 shares in the last quarter. Jump Financial LLC acquired a new stake in Immunome in the fourth quarter valued at approximately $172,000. Sequoia Financial Advisors LLC acquired a new stake in Immunome in the second quarter valued at approximately $206,000. Finally, Clear Creek Financial Management LLC grew its position in Immunome by 18.2% in the second quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock valued at $317,000 after acquiring an additional 4,035 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.
Immunome Stock Performance
Shares of NASDAQ IMNM opened at $15.45 on Wednesday. The firm has a market capitalization of $926.52 million, a P/E ratio of -2.05 and a beta of 1.79. Immunome has a one year low of $6.13 and a one year high of $30.96. The company’s fifty day moving average is $13.89 and its two-hundred day moving average is $17.67.
Immunome (NASDAQ:IMNM – Get Free Report) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.46. The business had revenue of $1.03 million during the quarter, compared to the consensus estimate of $4.00 million. Immunome had a negative return on equity of 37.33% and a negative net margin of 1,829.44%. On average, sell-side analysts forecast that Immunome will post -1.45 earnings per share for the current fiscal year.
About Immunome
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Featured Articles
- Five stocks we like better than Immunome
- Stock Sentiment Analysis: How it Works
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- How to Invest in Biotech Stocks
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Business Services Stocks Investing
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.